- Home
- KZR
as 12-18-2024 9:53am EST
Kezar Life Sciences Inc is a clinical-stage biotechnology company. It is engaged in discovering and developing novel small molecule therapeutics to treat unmet needs in autoimmunity and cancer. The pipeline consist of product candidates such as Zetomipzomib (KZR-616), and KZR-261.
| Founded: | 2015 | Country: | United States |
| Employees: | N/A | City: | SOUTH SAN FRANCISCO |
| Market Cap: | 54.1M | IPO Year: | 2018 |
| Target Price: | $11.00 | AVG Volume (30 days): | 61.0K |
| Analyst Decision: | Hold | Number of Analysts: | 2 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -13.15 | EPS Growth: | N/A |
| 52 Week Low/High: | $5.20 - $11.40 | Next Earning Date: | 11-12-2024 |
| Revenue: | N/A | Revenue Growth: | N/A |
| Revenue Growth (this year): | N/A | Revenue Growth (next year): | N/A |
Latest Kezar Life Sciences Inc. News
KZR Breaking Stock News: Dive into KZR Ticker-Specific Updates for Smart Investing
Clinical Trials Arena
a month ago
Kezar struck again with second FDA hold
MT Newswires
2 months ago
Kezar Life Sciences to Implement 1-for-10 Reverse Stock Split
Business Wire
2 months ago
Kezar Life Sciences Announces 1-for-10 Reverse Stock Split
Clinical Trials Arena
2 months ago
Kezar Life Sciences discontinues lupus nephritis programme after fatalities
MT Newswires
2 months ago
Kezar Life Sciences Gets Nod to Proceed With Autoimmune Hepatitis Trial; Ends Lupus Nephritis Study
Benzinga
2 months ago
Penny Stock Kezar Life Sciences Rejects Acquisition Deal From Concentra Biosciences At $1.10/Share, Shelves Mid-Stage Lupus Nephritis Study
MT Newswires
2 months ago
Kezar Life Sciences Rejects Concentra Biosciences Takeover Bid, Adopts Rights Plan
Business Wire
2 months ago
Kezar Board Unanimously Rejects Unsolicited Concentra Proposal and Adopts Limited Duration Stockholder Rights Plan
Compare KZR vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "KZR Kezar Life Sciences Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.